卡铂-话题@MedSci

#卡铂#

64篇内容 | 2684人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1396312, encodeId=c0c0139631200, content=<a href='/topic/show?id=9dc636545a4' target=_blank style='color:#2F92EE;'>#卡铂#</a>, objectTitle=Ann Oncol：纳武利尤单抗（Nivolumab）联合卡铂、紫杉醇和贝伐珠单抗一线治疗晚期非鳞状非小细胞肺癌的疗效和安全性, objectType=article, longId=213326, objectId=17162133260e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=17162133260e, replyNumber=0, likeNumber=83, createdTime=2021-06-28, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=17162133260e, moduleTitle=Ann Oncol：纳武利尤单抗（Nivolumab）联合卡铂、紫杉醇和贝伐珠单抗一线治疗晚期非鳞状非小细胞肺癌的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=17162133260e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1396311, encodeId=e2e41396311e7, content=<a href='/topic/show?id=9dc636545a4' target=_blank style='color:#2F92EE;'>#卡铂#</a>, objectTitle=Eur J Cancer：奥沙利铂/卡培他滨联合放疗（OxCapRT）对比紫杉醇/卡铂联合放疗（CarPacRT）新辅助治疗对可切除食管腺癌的疗效和安全性：NeoSCOPE长期随访结果, objectType=article, longId=213266, objectId=96fd2132664f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=96fd2132664f, replyNumber=0, likeNumber=56, createdTime=2021-06-27, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=96fd2132664f, moduleTitle=Eur J Cancer：奥沙利铂/卡培他滨联合放疗（OxCapRT）对比紫杉醇/卡铂联合放疗（CarPacRT）新辅助治疗对可切除食管腺癌的疗效和安全性：NeoSCOPE长期随访结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=96fd2132664f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1396310, encodeId=bde8139631099, content=<a href='/topic/show?id=9dc636545a4' target=_blank style='color:#2F92EE;'>#卡铂#</a>, objectTitle=JCO：复发性卵巢癌可否从二次减瘤术时卡铂腹腔热灌注化疗中获益？, objectType=article, longId=211980, objectId=f93f211980ae, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f93f211980ae, replyNumber=0, likeNumber=78, createdTime=2021-05-30, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f93f211980ae, moduleTitle=JCO：复发性卵巢癌可否从二次减瘤术时卡铂腹腔热灌注化疗中获益？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f93f211980ae)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1396309, encodeId=5e8c1396309de, content=<a href='/topic/show?id=9dc636545a4' target=_blank style='color:#2F92EE;'>#卡铂#</a>, objectTitle=CLIN CANCER RES：一种新的治疗组合——NUC-1031联合卡铂治疗复发性卵巢癌, objectType=article, longId=208795, objectId=2961208e956a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2961208e956a, replyNumber=0, likeNumber=54, createdTime=2021-03-22, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2961208e956a, moduleTitle=CLIN CANCER RES：一种新的治疗组合——NUC-1031联合卡铂治疗复发性卵巢癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2961208e956a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1396308, encodeId=28cb1396308b7, content=<a href='/topic/show?id=9dc636545a4' target=_blank style='color:#2F92EE;'>#卡铂#</a>, objectTitle=J Clin Oncol：贝伐单抗+卡铂+紫杉醇可明显改善转移性粘膜黑色素瘤的预后, objectType=article, longId=206293, objectId=d65b206293e7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d65b206293e7, replyNumber=0, likeNumber=92, createdTime=2021-01-28, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d65b206293e7, moduleTitle=J Clin Oncol：贝伐单抗+卡铂+紫杉醇可明显改善转移性粘膜黑色素瘤的预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d65b206293e7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1396307, encodeId=a911139630e21, content=<a href='/topic/show?id=9dc636545a4' target=_blank style='color:#2F92EE;'>#卡铂#</a>, objectTitle=【瞩目】铂敏感复发性卵巢癌：卡铂-多柔比星-贝伐珠单抗或许是新的标准治疗方案, objectType=article, longId=206078, objectId=28d22060e857, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=28d22060e857, replyNumber=0, likeNumber=69, createdTime=2021-01-24, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=28d22060e857, moduleTitle=【瞩目】铂敏感复发性卵巢癌：卡铂-多柔比星-贝伐珠单抗或许是新的标准治疗方案, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=28d22060e857)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1396306, encodeId=52df13963060a, content=<a href='/topic/show?id=9dc636545a4' target=_blank style='color:#2F92EE;'>#卡铂#</a>, objectTitle= J Clin Oncol：卡铂/依托泊苷方案+阿妥珠单抗作为广泛期小细胞肺癌一线治疗方案的延长随访预后结果（IMpower133试验）, objectType=article, longId=205905, objectId=050d20590572, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=050d20590572, replyNumber=0, likeNumber=107, createdTime=2021-01-21, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=050d20590572, moduleTitle= J Clin Oncol：卡铂/依托泊苷方案+阿妥珠单抗作为广泛期小细胞肺癌一线治疗方案的延长随访预后结果（IMpower133试验）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=050d20590572)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1396305, encodeId=9f751396305f9, content=<a href='/topic/show?id=9dc636545a4' target=_blank style='color:#2F92EE;'>#卡铂#</a>, objectTitle=Lancet oncol：ICON8试验| 卵巢、输卵管、腹膜癌经卡铂-紫杉醇一线新辅助化疗后的客观缓解率, objectType=article, longId=205053, objectId=bd212050532b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bd212050532b, replyNumber=0, likeNumber=57, createdTime=2021-01-01, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bd212050532b, moduleTitle=Lancet oncol：ICON8试验| 卵巢、输卵管、腹膜癌经卡铂-紫杉醇一线新辅助化疗后的客观缓解率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bd212050532b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1396304, encodeId=2883139630473, content=<a href='/topic/show?id=9dc636545a4' target=_blank style='color:#2F92EE;'>#卡铂#</a>, objectTitle=Lancet oncol：PARP抑制剂veliparib联合卡铂-紫杉醇治疗BRCA突变的晚期乳腺癌的疗效, objectType=article, longId=200007, objectId=6f2b20000e60, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6f2b20000e60, replyNumber=0, likeNumber=0, createdTime=2020-08-30, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6f2b20000e60, moduleTitle=Lancet oncol：PARP抑制剂veliparib联合卡铂-紫杉醇治疗BRCA突变的晚期乳腺癌的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6f2b20000e60)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1396303, encodeId=9006139630332, content=<a href='/topic/show?id=9dc636545a4' target=_blank style='color:#2F92EE;'>#卡铂#</a>, objectTitle=J Clin Oncol：转移性鳞状非小细胞肺癌患者中使用卡铂-紫杉醇联合培博利珠单抗可改善患者的生活质量, objectType=article, longId=199699, objectId=d1b8199699d0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d1b8199699d0, replyNumber=0, likeNumber=0, createdTime=2020-08-21, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d1b8199699d0, moduleTitle=J Clin Oncol：转移性鳞状非小细胞肺癌患者中使用卡铂-紫杉醇联合培博利珠单抗可改善患者的生活质量, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d1b8199699d0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1396302, encodeId=b82413963029e, content=<a href='/topic/show?id=9dc636545a4' target=_blank style='color:#2F92EE;'>#卡铂#</a>, objectTitle=J Clin Oncol：吉非替尼VS吉非替尼加培美曲塞和卡铂化疗在EGFR突变肺癌中的对比分析, objectType=article, longId=198499, objectId=8e7819849955, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8e7819849955, replyNumber=0, likeNumber=72, createdTime=2020-08-02, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8e7819849955, moduleTitle=J Clin Oncol：吉非替尼VS吉非替尼加培美曲塞和卡铂化疗在EGFR突变肺癌中的对比分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8e7819849955)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1396301, encodeId=6bc81396301c3, content=<a href='/topic/show?id=9dc636545a4' target=_blank style='color:#2F92EE;'>#卡铂#</a>, objectTitle=AACR 2020：PD-L1单抗Tecentriq联合卡铂和依托泊苷，可提高小细胞肺癌SCLC生存率, objectType=article, longId=196545, objectId=5a8619654517, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5a8619654517, replyNumber=0, likeNumber=49, createdTime=2020-06-28, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5a8619654517, moduleTitle=AACR 2020：PD-L1单抗Tecentriq联合卡铂和依托泊苷，可提高小细胞肺癌SCLC生存率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5a8619654517)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1396300, encodeId=ae4b139630054, content=<a href='/topic/show?id=9dc636545a4' target=_blank style='color:#2F92EE;'>#卡铂#</a>, objectTitle=Int J Clin Oncol：卡铂或西妥昔单抗加放疗对不能接受顺铂治疗的局部晚期头颈部癌症患者的安全性和有效性, objectType=article, longId=196267, objectId=c95e19626e25, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c95e19626e25, replyNumber=0, likeNumber=66, createdTime=2020-06-24, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c95e19626e25, moduleTitle=Int J Clin Oncol：卡铂或西妥昔单抗加放疗对不能接受顺铂治疗的局部晚期头颈部癌症患者的安全性和有效性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c95e19626e25)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1396299, encodeId=2348139629911, content=<a href='/topic/show?id=9dc636545a4' target=_blank style='color:#2F92EE;'>#卡铂#</a>, objectTitle=Lancet oncol：3期试验：卡铂-聚乙醇化脂质体多柔比星-贝伐珠单抗治疗铂敏感性复发性卵巢癌的疗效, objectType=article, longId=192935, objectId=dc37192935a7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dc37192935a7, replyNumber=0, likeNumber=0, createdTime=2020-04-26, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dc37192935a7, moduleTitle=Lancet oncol：3期试验：卡铂-聚乙醇化脂质体多柔比星-贝伐珠单抗治疗铂敏感性复发性卵巢癌的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dc37192935a7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1396298, encodeId=efe91396298c7, content=<a href='/topic/show?id=9dc636545a4' target=_blank style='color:#2F92EE;'>#卡铂#</a>, objectTitle=Lancet oncol：卡巴他赛联合卡铂治疗去雄耐受性的转移性前列腺癌, objectType=article, longId=179257, objectId=a1d11e925723, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a1d11e925723, replyNumber=0, likeNumber=51, createdTime=2019-09-12, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a1d11e925723, moduleTitle=Lancet oncol：卡巴他赛联合卡铂治疗去雄耐受性的转移性前列腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a1d11e925723)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1396297, encodeId=ba09139629eea, content=<a href='/topic/show?id=9dc636545a4' target=_blank style='color:#2F92EE;'>#卡铂#</a>, objectTitle=Lancet Oncol：Trebananib联合紫杉醇和卡铂作为一线疗法用于晚期卵巢癌患者的疗效和安全性, objectType=article, longId=166883, objectId=967c166883ab, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=967c166883ab, replyNumber=0, likeNumber=59, createdTime=2019-05-28, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=967c166883ab, moduleTitle=Lancet Oncol：Trebananib联合紫杉醇和卡铂作为一线疗法用于晚期卵巢癌患者的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=967c166883ab)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1396296, encodeId=72781396296a1, content=<a href='/topic/show?id=9dc636545a4' target=_blank style='color:#2F92EE;'>#卡铂#</a>, objectTitle=CLIN CANCER RES：Veliparib联合卡铂和依托泊苷治疗非小细胞肺癌和其它实体肿瘤, objectType=article, longId=159009, objectId=1690159009ef, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1690159009ef, replyNumber=0, likeNumber=79, createdTime=2019-01-28, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1690159009ef, moduleTitle=CLIN CANCER RES：Veliparib联合卡铂和依托泊苷治疗非小细胞肺癌和其它实体肿瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1690159009ef)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1396295, encodeId=c0fc139629534, content=<a href='/topic/show?id=9dc636545a4' target=_blank style='color:#2F92EE;'>#卡铂#</a>, objectTitle=JCO：卡铂和紫杉醇对未知原发癌患者的部位特异性治疗：II期临床试验, objectType=article, longId=158471, objectId=e6371584e194, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e6371584e194, replyNumber=0, likeNumber=102, createdTime=2019-01-21, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e6371584e194, moduleTitle=JCO：卡铂和紫杉醇对未知原发癌患者的部位特异性治疗：II期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e6371584e194)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1396294, encodeId=4e26139629418, content=<a href='/topic/show?id=9dc636545a4' target=_blank style='color:#2F92EE;'>#卡铂#</a>, objectTitle=CLIN CANCER RES：三阴性乳腺癌患者新辅助卡铂联合多西紫杉醇治疗后病情缓解情况及预后, objectType=article, longId=155771, objectId=2def155e7198, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2def155e7198, replyNumber=0, likeNumber=68, createdTime=2018-12-15, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2def155e7198, moduleTitle=CLIN CANCER RES：三阴性乳腺癌患者新辅助卡铂联合多西紫杉醇治疗后病情缓解情况及预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2def155e7198)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1396293, encodeId=6f6c13962935b, content=<a href='/topic/show?id=9dc636545a4' target=_blank style='color:#2F92EE;'>#卡铂#</a>, objectTitle=ANN ONCOL：蛋白结合型紫杉醇联合卡铂或吉西他滨治疗转移性三阴性乳腺癌, objectType=article, longId=147408, objectId=1ea914e40885, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1ea914e40885, replyNumber=0, likeNumber=74, createdTime=2018-08-27, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1ea914e40885, moduleTitle=ANN ONCOL：蛋白结合型紫杉醇联合卡铂或吉西他滨治疗转移性三阴性乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1ea914e40885)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

卡铂

2020-05-29

智者为医08 (审核中...)

前往app查看评论内容

#卡铂#

Ann Oncol：纳武利尤单抗（Nivolumab）联合卡铂、紫杉醇和贝伐珠单抗一线治疗晚期非鳞状非小细胞肺癌的疗效和安全性

2021-06-28

智者为医08 (审核中...)

前往app查看评论内容

#卡铂#

Eur J Cancer：奥沙利铂/卡培他滨联合放疗（OxCapRT）对比紫杉醇/卡铂联合放疗（CarPacRT）新辅助治疗对可切除食管腺癌的疗效和安全性：NeoSCOPE长期随访结果

2021-06-27

智者为医08 (审核中...)

前往app查看评论内容

#卡铂#

JCO：复发性卵巢癌可否从二次减瘤术时卡铂腹腔热灌注化疗中获益？

2021-05-30

智者为医08 (审核中...)

前往app查看评论内容

#卡铂#

CLIN CANCER RES：一种新的治疗组合——NUC-1031联合卡铂治疗复发性卵巢癌

2021-03-22

智者为医08 (审核中...)

前往app查看评论内容

#卡铂#

J Clin Oncol：贝伐单抗+卡铂+紫杉醇可明显改善转移性粘膜黑色素瘤的预后

2021-01-28

智者为医08 (审核中...)

前往app查看评论内容

#卡铂#

【瞩目】铂敏感复发性卵巢癌：卡铂-多柔比星-贝伐珠单抗或许是新的标准治疗方案

2021-01-24

智者为医08 (审核中...)

前往app查看评论内容

#卡铂#

J Clin Oncol：卡铂/依托泊苷方案+阿妥珠单抗作为广泛期小细胞肺癌一线治疗方案的延长随访预后结果（IMpower133试验）

2021-01-21

智者为医08 (审核中...)

前往app查看评论内容

#卡铂#

Lancet oncol：ICON8试验| 卵巢、输卵管、腹膜癌经卡铂-紫杉醇一线新辅助化疗后的客观缓解率

2021-01-01

智者为医08 (审核中...)

前往app查看评论内容

#卡铂#

Lancet oncol：PARP抑制剂veliparib联合卡铂-紫杉醇治疗BRCA突变的晚期乳腺癌的疗效

2020-08-30

智者为医08 (审核中...)

前往app查看评论内容

#卡铂#

J Clin Oncol：转移性鳞状非小细胞肺癌患者中使用卡铂-紫杉醇联合培博利珠单抗可改善患者的生活质量

2020-08-21

智者为医08 (审核中...)

前往app查看评论内容

#卡铂#

J Clin Oncol：吉非替尼VS吉非替尼加培美曲塞和卡铂化疗在EGFR突变肺癌中的对比分析

2020-08-02

智者为医08 (审核中...)

前往app查看评论内容

#卡铂#

AACR 2020：PD-L1单抗Tecentriq联合卡铂和依托泊苷，可提高小细胞肺癌SCLC生存率

2020-06-28

智者为医08 (审核中...)

前往app查看评论内容

#卡铂#

Int J Clin Oncol：卡铂或西妥昔单抗加放疗对不能接受顺铂治疗的局部晚期头颈部癌症患者的安全性和有效性

2020-06-24

智者为医08 (审核中...)

前往app查看评论内容

#卡铂#

Lancet oncol：3期试验：卡铂-聚乙醇化脂质体多柔比星-贝伐珠单抗治疗铂敏感性复发性卵巢癌的疗效

2020-04-26

智者为医08 (审核中...)

前往app查看评论内容

#卡铂#

Lancet oncol：卡巴他赛联合卡铂治疗去雄耐受性的转移性前列腺癌

2019-09-12

智者为医08 (审核中...)

前往app查看评论内容

#卡铂#

Lancet Oncol：Trebananib联合紫杉醇和卡铂作为一线疗法用于晚期卵巢癌患者的疗效和安全性

2019-05-28

智者为医08 (审核中...)

前往app查看评论内容

#卡铂#

CLIN CANCER RES：Veliparib联合卡铂和依托泊苷治疗非小细胞肺癌和其它实体肿瘤

2019-01-28

智者为医08 (审核中...)

前往app查看评论内容

#卡铂#

JCO：卡铂和紫杉醇对未知原发癌患者的部位特异性治疗：II期临床试验

2019-01-21

智者为医08 (审核中...)

前往app查看评论内容

#卡铂#

CLIN CANCER RES：三阴性乳腺癌患者新辅助卡铂联合多西紫杉醇治疗后病情缓解情况及预后

2018-12-15

智者为医08 (审核中...)

前往app查看评论内容

#卡铂#

ANN ONCOL：蛋白结合型紫杉醇联合卡铂或吉西他滨治疗转移性三阴性乳腺癌

2018-08-27

科室
- - 订阅+
  - 更多科室
工具
服务